Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (vol 29, pg 1843, 2018)

Collapse authors list.
Corrie, PG, Marshall, A, Nathan, PD, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, CG, Marples, M, Danson, SJ et al (show 28 more authors) , Marshall, E, Houston, SJ, Board, RE, Waterston, AM, Nobes, JP, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, PM, Ottensmeier, CH ORCID: 0000-0003-3619-1657, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, EO, Harman, C, Weiss, M, Myers, KA, Chhabra, A, Rodwell, SH, Dunn, JA and Middleton, MR (2019) Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (vol 29, pg 1843, 2018). ANNALS OF ONCOLOGY, 30 (12). pp. 2013-2014.

Text Adjuvant bevacizumab for melanoma patients at high risk of recurrence survival analysis of the AVAST-M trial.pdf - Published version Download (816kB) | Preview

Abstract

In the original article, there was an error in Figure 3. The figure has now been corrected as below in the online version of the article.

Item Type:	Article
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User:	Symplectic Admin
Date Deposited:	22 Dec 2021 09:19
Last Modified:	15 Mar 2024 17:20
DOI:	10.1093/annonc/mdz237
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3145823